[The role of PPARgamma agonists in kidney diseases].
Peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-dependent transcription factor that has a central role in the regulation of insulin sensitivity and adipocyte differentiation. Expression of PPARgamma has been reported in the kidney, including medullary collecting ducts, glomeruli and tubular cells. Thiazolidinediones (TZDs) are synthetic PPARgamma agonists and are used widely in patients with type 2 diabetes. It has been gradually discovered that TZDs have various other actions, such as vascular protective, anti-inflammatory, anti-fibrotic and anti-proliferative actions, over and above their effects on glucose and lipid metabolism. In this review, we will focus on current knowledge and insights on the role of PPARgamma agonists in kidney diseases, especially in diabetic nephropathy, non-diabetic kidney diseases and dialysis therapy.
Yokoyama
Yukio
Y
Department of Advanced Nephrology, Graduate School of Biomedical Sciences, Hiroshima University.
Doi
Shigehiro
S
Kawai
Toru
T
Yorioka
Noriaki
N
D000818:Animals; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy*; D047495:PPAR gamma / Q000819:agonists*
D047495:PPAR gamma